• Dilbar Makhkamova Tashkent Institute of Postgraduate Medical Education, Department of Ophthalmology, Tashkent
Keywords: ocular ischemic syndrome, the treatment of ischemic diseases of the eye, FDP, metabolic therapy of ocular ischemic syndrome.


The purpose of this study was to evaluate the efficacy and safety of FDP in patients with ocular ischemic syndrome.

Material and methods. The material for this study is based on results of a comprehensive examination and treatment of 53 patients with a diagnosis OIS. The average age of the patients was 57,8 ± 6,82 year. 19 of them women, 34 men.  27 patients entered to the main group (1) which received standard therapy in combination with intravenous FDP (fructose 1,6-bisphosphate). 26 patients in the control group (2) received standard treatment.

Results.  In applying the FDP combined with comprehensive therapy in the main group resulted in increased of visual acuity by 32.8%, parameters of retinal sensitivity by 17.8%, reducing the area of scotomas compared with patients of the control group. Optical coherence tomography registered significant changes in the dynamics in patients of the main group - reducing the edema and restoration of  RNFL and ONH. Recovery of visual function may have contributed neuroprotective activity of the drug FDP by a protective effect on nerve tissue, reducing the effects of hypoxic stress.

Conclusions. The use of standard therapy in combination with FDP in the treatment of ocular ischemic syndrome has a positive effect on the course of the disease, thereby, increase of visual acuity, a decrease in sectoral loss in vision fields, the positive dynamics OCT parameters, improving hemodynamic parameters at Doppler imaging in dynamics.


Barbara, Terelak-Borys, Katarzyna, Skonieczna, Iwona, Grabska-Liberek, (2012) Ocular ischemic syndrome – a systematic review. Med Sci Monit. 18(8): RA138–RA144. [PubMed]

Cacioli, D., Clivati, A., Pelosi, P., Megevand, J., Galeone, M., (1988). Hemorheologic effects of fructose1,6-diphosphate in patients with limb ischemia. Curr. Med. Res. Opin.Vol10ISS 10 P668-674, (Ref18) [PubMed]

Karaca, M., Kilic, E., Yazici, B., Demir, S., Torre, J.C., (2002). Treatment of ischemic stroke in elderly patients with a solution containing a free radical scavenger-intermediate of glycolysis: a pilot study.Neurol.Res., Jan;24(I):73-80[PubMed]

Kearns, T.P., Hollenhorst, R.W., (1963). Venous stasis retinopathy of occlusive disease of the carotid artery. Mayo Clin Proc.38:304–12. [PubMed]

Marchezani, F., Valerio, G., Dardes, N., Viglianti, B., Sanguinetti, C.M., (2000). Effect of intravenous administration of fructose 1,6-diphosphate in patients with chronic obstructive pulmonary disease. Respiration, 67(2):177-182. [PubMed].

Mendrinos, E., Machinie, T.G., Pournaras, C.J., (2010). Ocular Ischemic Syndrome. Surv Ophthalmol.55(1):2–34. [PubMed]

Mizener, J.B., Podhajsky, P., Hayreh, S.S., (1997). Ocular ischemic syndrome. Ophthalmology. 104(5):859–64. [PubMed]

Odero, A., Kunkl, E., Cugnasca, M., De, Amicis, P., Marchetti, M., (1985). Fructose 1,6- diphosphate in the treatment of peripheral vascular diseases: assessment of clinical efficacy in patients with limb ischemia. CurrTher.Res. Vol 38 ISS Sep P396-403,(Ref17) [PubMed]

Paul, J., Marangos, Anthony, W. Fox, Bernhard, J. Riedel, David, Royston, Zofia, E. Dziewanowska, (1998). Cypros Pharmaceutical Corporation. Potential therapeutic applications of fructose-1,6-diphosphate. Expert Opinion on Investigational Drugs. April Vol. 7, No. 4 , Pages 615-623 (doi:10.1517/13543784.7.4.615) 2714 [PubMed].

Riedel, B.J., Gal, J., Ellis, G., Marangos, P.J., Fox, A.W., Royston, D., (2004). Myocardial protection using fructose 1,6-diphosphat in operations coronary artery bypass surgery: a randomized, placebo – controlled clinical trial. Anesth Analg. Jan;98(I):20-29[PubMed]

Ryan SJ, Hinton DR, Schachat AP, (2004). Elsevier; pp.1491–502. [PubMed]

Sharma, S., Brown, G.C., (2006). In: Ocular Ischemic Syndrome. [PubMed]

Sivalingam, A., Brown, G.C., Magargal, L.E., (1991). The ocular ischemic syndrome. III. Visual prognosis and the effect of treatment. Int Ophthalmol. 15(1):15–20. [PubMed]